Indeed, biologics designed around CTLA-4, such as CTLA-4 fused to FcR (brand name Belatacept) have been used successfully to treat a variety of autoimmune diseases and in organ transplantation (56) (Figure 4), and show some efficacy in T1DM animal models and clinical trials. This evidence concerns the gene CTLA4 and autoimmune disease.